382 related articles for article (PubMed ID: 29915896)
1. Targeting EGFR in Lung Cancer: Current Standards and Developments.
Díaz-Serrano A; Gella P; Jiménez E; Zugazagoitia J; Paz-Ares Rodríguez L
Drugs; 2018 Jun; 78(9):893-911. PubMed ID: 29915896
[TBL] [Abstract][Full Text] [Related]
2. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
Goss GD; Spaans JN
Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
Husain H; Melnikova VO; Kosco K; Woodward B; More S; Pingle SC; Weihe E; Park BH; Tewari M; Erlander MG; Cohen E; Lippman SM; Kurzrock R
Clin Cancer Res; 2017 Aug; 23(16):4716-4723. PubMed ID: 28420725
[No Abstract] [Full Text] [Related]
4. An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
Mancini M; Gal H; Gaborit N; Mazzeo L; Romaniello D; Salame TM; Lindzen M; Mahlknecht G; Enuka Y; Burton DG; Roth L; Noronha A; Marrocco I; Adreka D; Altstadter RE; Bousquet E; Downward J; Maraver A; Krizhanovsky V; Yarden Y
EMBO Mol Med; 2018 Feb; 10(2):294-308. PubMed ID: 29212784
[TBL] [Abstract][Full Text] [Related]
5. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Karlsen EA; Kahler S; Tefay J; Joseph SR; Simpson F
Cells; 2021 May; 10(5):. PubMed ID: 34069119
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
Yu HA; Riely GJ; Lovly CM
Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
[TBL] [Abstract][Full Text] [Related]
7. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.
Maity S; Pai KSR; Nayak Y
Pharmacol Rep; 2020 Aug; 72(4):799-813. PubMed ID: 32666476
[TBL] [Abstract][Full Text] [Related]
8. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer.
Dienstmann R; De Dosso S; Felip E; Tabernero J
Mol Oncol; 2012 Feb; 6(1):15-26. PubMed ID: 22189054
[TBL] [Abstract][Full Text] [Related]
9. Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer.
Bai H; Zhou Y; Liu W; Xu WY; Cheng L; Huo Y; Ji H; Xiong L
Heliyon; 2024 Mar; 10(6):e27633. PubMed ID: 38496877
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer.
Pancewicz-Wojtkiewicz J
Cancer Med; 2016 Dec; 5(12):3572-3578. PubMed ID: 27770511
[TBL] [Abstract][Full Text] [Related]
11. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
12. Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned.
Belluomini L; Riva ST; Simbolo M; Nocini R; Trestini I; Avancini A; Tregnago D; Ferrara MG; Caldart A; Dodi A; Caliò A; Bria E; Scarpa A; Milella M; Menis J; Pilotto S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685665
[No Abstract] [Full Text] [Related]
13. Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer.
Adderley H; Blackhall FH; Lindsay CR
Cancer Immunol Immunother; 2021 Mar; 70(3):589-595. PubMed ID: 32915318
[TBL] [Abstract][Full Text] [Related]
14. Oral targeted therapy for the treatment of non-small cell lung carcinoma.
Phillips WJ; Leighl NB; Blais N; Wheatley-Price P
CMAJ; 2024 Apr; 196(16):E558-E561. PubMed ID: 38684283
[No Abstract] [Full Text] [Related]
15. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors.
Hussain S; Mursal M; Verma G; Hasan SM; Khan MF
Eur J Pharmacol; 2024 May; 970():176484. PubMed ID: 38467235
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment.
Maroni G; Krishnan I; Alfieri R; Maymi VA; Pandell N; Csizmadia E; Zhang J; Weetall M; Branstrom A; Braccini G; Cabrera San Millán E; Storti B; Bizzarri R; Kocher O; Daniela Sanchez Bassères DS; Welner RS; Magli MC; Merelli I; Clohessy JG; Ali A; Tenen DG; Levantini E
Cancer Res Commun; 2024 Mar; 4(3):919-937. PubMed ID: 38546390
[TBL] [Abstract][Full Text] [Related]
17. Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?
Hirsch FR
Transl Lung Cancer Res; 2014 Dec; 3(6):363-4. PubMed ID: 25806320
[No Abstract] [Full Text] [Related]
18. Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments.
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 May; ():. PubMed ID: 38739333
[No Abstract] [Full Text] [Related]
19. Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance.
Schrank Z; Chhabra G; Lin L; Iderzorig T; Osude C; Khan N; Kuckovic A; Singh S; Miller RJ; Puri N
Cancers (Basel); 2018 Jul; 10(7):. PubMed ID: 29973561
[TBL] [Abstract][Full Text] [Related]
20. Oncogene-addicted non-small cell lung cancer and immunotherapy.
Tsakonas G; Ekman S
J Thorac Dis; 2018 May; 10(Suppl 13):S1547-S1555. PubMed ID: 29951305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
